ArticleJournal of chemical information and modeling2026
Molecular Dynamics Simulation of Passive Diffusion across a Human Breast Cancer Cell Membrane Model. Comparison between Cisplatin and Its Pt(IV) Derivatives.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid-dependent regulation of Kv10.1 in cancer: implications of membrane remodeling for channel function and pharmacology.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of platinum(II) drugs, despite their wide use in clinical practice, is seriously limited by their well-known drawbacks. Octahedral Pt(IV) congeners are considered a sort of Holy Grail in cancer research as, being significantly more inert, they should be able to overcome the limitations of current platinum-based drugs, such as resistance and side effects, acting as prodrugs. Additionally, their anticancer activity can be tuned through a proper choice of the axial ligands released inside cancer cells when these compounds are reduced, making them even capable of potentially working as multiaction agents. However, despite their very satisfactory anticancer effects, no Pt(IV) complex has been approved for clinical use. As cell membrane permeation is the critical step, very poorly understood, of the whole mechanism of action of any drug, the investigation of the eventual differences in behavior between four-coordinate Pt(II) and six-coordinate Pt(IV) complexes when they diffuse in a lipid bilayer might be of significant relevance. The outcomes of a biased molecular dynamics (MD) investigation of the permeation of cisplatin and three simple cisplatin Pt(IV) derivatives through a membrane model prototype of human breast cancer cells are illustrated here. This comparative analysis of Pt(II) and Pt(IV) complex passive diffusion has been carried out with the aim of gaining indications about the factors that play a role in favoring or hindering membrane penetration and, ultimately, in determining the efficacy of their anticancer action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.